scholarly article | Q13442814 |
P2093 | author name string | Xavier Henry | |
Jacques Coyette | |||
Ana Amoroso | |||
Bernard Joris | |||
P2860 | cites work | In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci | Q24550612 |
Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users | Q24675979 | ||
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci | Q34162130 | ||
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae | Q34624359 | ||
Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium | Q35611120 | ||
Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy | Q36763997 | ||
In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus | Q36815290 | ||
The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis | Q37081708 | ||
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus | Q37204106 | ||
The epidemiology of enterococci | Q37909583 | ||
BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins | Q39470055 | ||
Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium | Q39477170 | ||
Bacterial active-site serine penicillin-interactive proteins and domains: mechanism, structure, and evolution | Q39537943 | ||
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | Q39650937 | ||
Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics | Q40157128 | ||
Active-site and membrane topology of the DD-peptidase/penicillin-binding protein no. 6 of Enterococcus hirae (Streptococcus faecium) A.T.C.C. 9790. | Q42163126 | ||
Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates | Q42747697 | ||
The 2.4-A crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin | Q44132103 | ||
Mode of membrane insertion and sequence of a 32-amino acid peptide stretch of the penicillin-binding protein 4 of Enterococcus hirae | Q68038173 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Enterococcus faecium | Q140010 |
P304 | page(s) | 953-955 | |
P577 | publication date | 2009-11-16 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium | |
P478 | volume | 54 |
Q37335869 | Activity of ceftaroline against Enterococcus faecium PBP5. |
Q26739860 | Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). |
Q38325502 | Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium |
Q46178941 | Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. |
Q28085517 | Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia |
Q36018587 | Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection model |
Q38539279 | Enterococcal endocarditis revisited |
Q26749531 | Glycosyltransferases and Transpeptidases/Penicillin-Binding Proteins: Valuable Targets for New Antibacterials |
Q55443184 | In silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens. |
Q36362547 | Intrinsic and acquired resistance mechanisms in enterococcus |
Q38712471 | One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams |
Q37796156 | The future of the β-lactams. |
Search more.